| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 10g | |||
| Other Sizes |
| Targets |
Quinine dihydrochloride targets potassium channels as an inhibitor, specifically WT mouse Slo3 (KCa5.1) channels with an IC50 of 169 μM. It also targets Plasmodium parasites as an antimalarial agent. The compound binds to parasite DNA, forming a complex that inhibits DNA replication and RNA transcription. It has antipyretic, analgesic, and anti-inflammatory properties.
|
|---|---|
| ln Vitro |
In the human liver cancer HepG2 cell line, quinine diHClide (150 μM, 30 min) suppresses the growth and cytostatic effects of dengue virus [1]. In the human liver cancer HepG2 cell line, quinine diHClide (37.5-150 μM, 24 hours) dramatically lowers viral DENV RNA and protein levels in a dose-dependent manner [1].
In vitro, Quinine dihydrochloride inhibits WT mouse Slo3 (KCa5.1) channel currents with an IC50 of 169 μM. It exhibits antimalarial activity by binding to parasite DNA. The compound has antipyretic, analgesic, and anti-inflammatory activities. Its potassium channel inhibitory and antimalarial activities have been characterized in various in vitro systems. |
| ln Vivo |
Quinine dihydrochloride has a certain inhibitory impact on skin cancer in Swiss albino mice when administered orally at a dose of 12 or 15 mg/kg once a week for 16 weeks [2]. The oral administration of quinine dihydrochloride (10 mg/kg, daily for 8 weeks) to adult male albino rats will result in a reduction in the activity of SOD, CAT, and GSH enzymes in their testicular tissue.
In vivo, Quinine dihydrochloride is an orally active antimalarial drug. It has tumor suppressing effects on skin cancer in Swiss albino mice at doses of 12 or 15 mg/kg orally every week for 16 weeks. The compound has antipyretic and analgesic properties and has been used in common cold preparations. It is also used to treat lupus and arthritis. |
| Enzyme Assay |
In vitro enzyme assays for Quinine dihydrochloride involve measuring potassium channel inhibition. Potassium channel activity is assessed using patch-clamp electrophysiology in cells expressing Slo3 channels. The compound is added at varying concentrations, and IC50 values are calculated from dose-response curves (IC50 = 169 μM). For antimalarial studies, Plasmodium cultures are used and parasite growth inhibition is measured.
|
| Cell Assay |
Cell proliferation assay [1]
Cell Types: Human hepatoma cell line (HepG2) Tested Concentrations: 150 μM Incubation Duration: 30 minutes Experimental Results: Compared with untreated, DENV virus replication was inhibited and the yield reached 19%. diminished DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner. In vitro cell-based assays for Quinine dihydrochloride are conducted in Plasmodium cultures and cancer cell lines. Plasmodium parasites are cultured in appropriate media and treated with the compound at varying concentrations. Parasite growth is monitored. For potassium channel studies, cells expressing Slo3 channels are used. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls. |
| Animal Protocol |
Animal/Disease Models: Swiss albino mice 7-8 weeks (weight 24 grams) [2]
Doses: 12 mg/kg, 15 mg/kg Route of Administration: po (oral gavage); weekly; 16-week Experimental Results: 12 mg/kg dose Tumor size and weight were Dramatically diminished at 15 mg/kg, with little effect at higher doses of 15 mg/kg. Quinine dihydrochloride in vivo studies are conducted in animal models of malaria and cancer. Animals are treated with the compound via oral administration. For antimalarial studies, Plasmodium-infected animals are used and parasitemia is monitored. For cancer studies, tumor-bearing mice are treated and tumor growth is monitored. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis. Studies are conducted in accordance with institutional animal care guidelines. |
| ADME/Pharmacokinetics |
Quinine dihydrochloride (MW 397.34 g/mol, C20H24N2O2·2HCl) is an orally active antimalarial alkaloid. It is soluble in water and other appropriate solvents. It is stable under recommended storage conditions but turns yellow on exposure to light. Quinine dihydrochloride is a potassium channel inhibitor and has antipyretic, analgesic, and anti-inflammatory properties. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution have been characterized in clinical studies.
|
| Toxicity/Toxicokinetics |
Quinine dihydrochloride is generally well-tolerated at therapeutic doses. The compound is an antimalarial drug with established safety profiles. It has antipyretic, analgesic, and anti-inflammatory properties. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation is available from clinical use data.
|
| References |
|
| Additional Infomation |
Quinine dihydrochloride is an orally active alkaloid extracted from cinchona bark used as an antimalarial drug. It inhibits WT mouse Slo3 (KCa5.1) potassium channels with an IC50 of 169 μM. The compound has antipyretic, analgesic, and anti-inflammatory properties. It is used to treat lupus and arthritis and as a flavor component in beverages. Its molecular formula is C20H24N2O2·2HCl with a molecular weight of 397.34 g/mol.All applications are limited to non-human research use.
|
| Molecular Formula |
C20H24N2O2.2(HCL)
|
|---|---|
| Molecular Weight |
397.34
|
| Exact Mass |
396.137
|
| CAS # |
60-93-5
|
| Related CAS # |
Quinine;130-95-0;Quinine hemisulfate hydrate;207671-44-1
|
| PubChem CID |
16211283
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
495.9ºC at 760 mmHg
|
| Melting Point |
238-2400C
|
| Flash Point |
253.7ºC
|
| LogP |
4.715
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
457
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O[C@H](C1=C2C=C(C=CC2=NC=C1)OC)[C@H]3N4CC[C@@]([H])(C3)[C@@H](C=C)C4.[H]Cl.[H]Cl
|
| InChi Key |
MPQKYZPYCSTMEI-FLZPLBAKSA-N
|
| InChi Code |
InChI=1S/C20H24N2O2.ClH.2H2O/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;;;/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1H;2*1H2/t13-,14-,19-,20+;;;/m0.../s1
|
| Chemical Name |
(1R)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol dihydrochloride
|
| Synonyms |
Quinine di-HCl CCRIS5754 CCRIS-5754 CCRIS 5754
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5167 mL | 12.5837 mL | 25.1674 mL | |
| 5 mM | 0.5033 mL | 2.5167 mL | 5.0335 mL | |
| 10 mM | 0.2517 mL | 1.2584 mL | 2.5167 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
